How this instrument works
In the United States, melatonin is sold over the counter as a dietary supplement, not regulated by the FDA as a drug for treating sleep problems in children or adults. That means there is no FDA-approved pediatric dosing label to look up the way there would be for a prescription sleep medication, and it's part of why organized clinical guidance on pediatric dosing has been slow to catch up with how widely melatonin is actually used in children.
This calculator's age tiers come from a 2025 international expert consensus statement — Owens, Simakajornboon, Kotagal, Gringras, et al., published in Sleep Medicine, 2025;128:127-129, on behalf of the International Pediatric Sleep Association (IPSA). It is explicitly labeled expert-consensus-grade guidance: the product of a task force of pediatric sleep clinicians and researchers reviewing the available evidence and publishing shared recommendations, rather than a chart derived from controlled trials that directly compared different doses in children.
The consensus statement sets a suggested maximum dose by age band, rising from no recommended dose at all under age 2, to 1 mg for ages 2-3, 2 mg for ages 4-5, 3 mg for ages 6-10, and 5 mg for ages 11 and up. Even within a tier, the statement frames these as ceilings rather than starting points — for the older tiers in particular, it describes typically starting around 0.5 mg and titrating upward roughly weekly, rather than beginning at the maximum figure this calculator returns.
This tool performs the age-tier lookup only. It doesn't account for a child's individual medical history, other medications, or the reason melatonin is being considered, all of which matter for whether and how much to use. The consensus statement itself, and the pediatricians who apply it, remain the right source for an individualized decision.
- Enter the child's age in years in Age (years).
- Read Suggested maximum dose (mg) for the age-tiered ceiling this consensus chart gives.
- Treat the result as a maximum, not a starting dose — the consensus statement describes starting around 0.5 mg and titrating upward roughly weekly, especially for older children.
- Confirm any use with a pediatrician first, particularly for younger children or for regular, long-term use.
Worked example — three ages, three tiers
A 1-year-old entered in Age (years) returns a suggested maximum dose of 0 mg — the 2025 IPSA consensus statement does not recommend melatonin for infants and toddlers under 2, regardless of the sleep difficulty being considered.
An 8-year-old falls into the school-age 6-10 tier, so the calculator returns a suggested maximum of 3 mg — the ceiling the consensus statement lists for that age band, not necessarily the dose a clinician would start with.
A 14-year-old falls into the 11-and-up tier, where the suggested maximum rises to 5 mg. The consensus statement notes that even at this top tier, clinicians typically start around 0.5 mg and titrate upward roughly weekly rather than beginning at the 5 mg ceiling.
Questions
Is this FDA-approved dosing guidance?
No. Melatonin is sold in the US as an over-the-counter dietary supplement, not an FDA-approved drug for treating sleep problems in children, so there is no official FDA pediatric dosing label to draw from. This calculator instead applies the age-tiered chart from a 2025 international expert consensus statement published by pediatric sleep specialists, which the statement itself labels expert-consensus-grade rather than trial-derived.
What does 'expert consensus' mean here, as opposed to a clinical trial result?
It means the age-tiered figures reflect the collective clinical judgment of an international task force of pediatric sleep researchers and clinicians — Owens, Simakajornboon, Kotagal, Gringras, and colleagues, publishing on behalf of the International Pediatric Sleep Association in 2025 — who reviewed the available evidence and published shared recommendations. It is not the same as a dosing chart built from randomized controlled trials that directly compared multiple doses head-to-head in children, because that kind of trial evidence largely doesn't exist yet for pediatric melatonin.
Why isn't melatonin recommended at all under age 2?
The IPSA consensus chart begins at age 2 and gives no suggested dose below that, reflecting how little pediatric evidence exists for melatonin use in infants and toddlers. Rather than extrapolate a dose downward without evidence to support it, the consensus statement simply doesn't offer one for that age group.
Should a child start at the suggested maximum dose?
No. The consensus statement frames these age-tiered figures as ceilings, not starting points. It describes typically beginning around 0.5 mg and titrating the dose upward roughly weekly if needed, rather than starting at the maximum the calculator returns for a given age — particularly for the older age tiers where that maximum is highest.
What input does this calculator use?
Just the child's age in years, entered in Age (years). The calculator looks up which of the five published age tiers that age falls into and returns the suggested maximum dose in milligrams for that tier.
Can this replace a conversation with a pediatrician?
No. This tool performs the age-tier lookup from a published consensus chart; it doesn't account for a child's individual health history, other medications, or the reason melatonin is being considered. The consensus statement itself recommends confirming use with a pediatrician, especially for younger children or for regular, long-term use, and that guidance applies here too.
References
Read this first: This instrument computes a screening figure from population formulas — it is not a diagnosis, and it cannot see the whole picture a clinician can. Use it to inform a conversation, not to replace one.